Genetic Diagnostic Tests: A Growing Market
Filed in archive Diagnostics, Methodologies and Instrumentation , Genomics, Proteomics and Bioinformatics by ruth on April 17, 2006
and possibly identify a patient's response to certain therapies. Here are some of the companies offering such diagnostic tests:- Genomic Health offers Oncotype DX, which identifies estrogen-sensitive cancer patients, who are responsive to hormone therapy, as an alternative to chemotherapy. Price: $3,500
- XDx offers a AlloMap, blood test that gauges the probability of a patient rejecting a transplanted heart. Price: $3,000
- Myriad Genetics offers BRACAnalysis, a test for the risk of developing breast and ovarian cancer; COLARIS and COLARIS AP for hereditary colorectal and endometrial cancer; and MELARIS for inherited susceptibility to melanoma and pancreatic cancer. Price (BRACAnalysis): $3,000
- Monogram Biosciences offers HIV assays that help gauge which antiretroviral drugs are best to treat a particular AIDS patient. Price: $1,460
- Exact Sciences offers a DNA-based colorectal cancer screening. Cost: $500
- Aureon Laboratories conducts ProstatePx, a combination of tests and uses a computer algorithm to predict recurrence of prostate cancer. Price: $2,000
These are just among the many diagnostic tests being developed out there. Whether medical insurances would shoulder the expenses or not, some patients would willingly shell out the money for the information they will obtain from such expensive tests. But is it ethical to leave access to such personalized medicine to the few who can afford it?
Permalink: Genetic Diagnostic Tests: A Growing Market
Tags:
cancer
diagnostics
tests
biotech
genetic
diagnostic+tests
genetic+diagnostic
growing+market
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/20064
Mr Wong
| 
